top of page
The Sound of Evolution
Ibrutinib
Mechanism of action:
Ibrutinib is a Bruton's tyrosine kinase inhibitor. Ibrutinib covalently binds to and inhibits the activity of Bruton's tyrosine kinase, blocking downstream NF-κB, PI3K-AKT, and MAPK pathways, ultimately suppressing B cell receptor (BCR)-related survival and proliferation signaling.
Reference(s):
1. Bagcchi S et al. (2015). Ibrutinib in pretreated Waldenstrom's macroglobulinaemia. Lancet Oncol.
2. Kim ES et al. (2015). Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia. Drugs.
3. Scheers E et al. (2015). Absorption, metabolism, and excretion of oral ¹⁴C-radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos.
bottom of page